U.S. FDA Grants RMAT Designation to ECT204, an ARTEMIS® CAR (AbTCR) T-Cell Therapy for Advanced Hepatocellular Carcinoma

EMERYVILLE, Calif. – January 12, 2026 – Eureka Therapeutics, Inc., a clinical-stage biotechnology company advancing next-generation T-cell therapies for cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to ECT204, a GPC3-targeting ARTEMIS® CAR T-cell therapy, for the treatment of patients with advanced hepatocellular carcinoma (HCC), The post U.S.